Joshua Epstein
Overview
Explore the profile of Joshua Epstein including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
85
Citations
5114
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mehdi S, Ghatak K, Ling W, Johnson S, Epstein J, Nookaew I, et al.
Leuk Res
. 2023 Jul;
133:107355.
PMID: 37499483
Bone marrow mesenchymal stem cells (MSCs) may have contrasting impacts on the progression of multiple myeloma (MM). Priming normal MSCs, by culturing them with MM cells, mimics the MSC-induced MM...
2.
Durie B, Hoering A, Sexton R, Abidi M, Epstein J, Rajkumar S, et al.
Blood Cancer J
. 2020 May;
10(5):53.
PMID: 32393732
SWOG S0777, a randomized phase III trial, compared bortezomib, lenalidomide and dexamethasone (VRd) with lenalidomide and dexamethasone (Rd). This updated analysis includes 460 patients evaluable for survival endpoints: 225 eligible...
3.
Rasche L, Kumar M, Gershner G, Samant R, Van Hemert R, Heidemeier A, et al.
Theranostics
. 2019 Aug;
9(16):4756-4763.
PMID: 31367255
Due to the low frequency of abnormalities affecting the spleen, this organ is often overlooked during radiological examinations. Here, we report on the unexpected finding, that the spleen signal on...
4.
Mehdi S, Johnson S, Epstein J, Zangari M, Qu P, Hoering A, et al.
Br J Haematol
. 2018 Nov;
184(4):578-593.
PMID: 30408155
Recent studies suggest that multiple myeloma (MM) induces proliferation and expansion of bone marrow (BM) mesenchymal stem cells (MSCs), but others showed that MM cells induce MSC senescence. To clarify...
5.
Qiang Y, Ye S, Huang Y, Chen Y, van Rhee F, Epstein J, et al.
BMC Cancer
. 2018 Jul;
18(1):724.
PMID: 29980194
Background: Multiple myeloma (MM) patients with t(14;20) have a poor prognosis and their outcome has not improved following the introduction of bortezomib (Bzb). The mechanism underlying the resistance to proteasome...
6.
Rasche L, Angtuaco E, Alpe T, Gershner G, McDonald J, Samant R, et al.
Blood
. 2018 May;
132(1):59-66.
PMID: 29784643
Spatial intratumor heterogeneity is frequently seen in multiple myeloma (MM) and poses a significant challenge for risk classifiers, which rely on tumor samples from the iliac crest. Because biopsy-based assessment...
7.
Schinke C, Qu P, Mehdi S, Hoering A, Epstein J, Johnson S, et al.
Clin Cancer Res
. 2018 Mar;
24(12):2913-2919.
PMID: 29563136
Mesenchymal stem cells (MSC) are an essential component of the bone marrow microenvironment and have shown to support cancer evolution in multiple myeloma. Despite the increasing evidence that multiple myeloma...
8.
Thanendrarajan S, Tian E, Qu P, Mathur P, Schinke C, van Rhee F, et al.
Haematologica
. 2017 May;
102(9):e364-e367.
PMID: 28550191
No abstract available.
9.
Schinke C, Hoering A, Wang H, Carlton V, Thanandrarajan S, Deshpande S, et al.
Haematologica
. 2017 May;
102(8):e313-e316.
PMID: 28522572
No abstract available.
10.
Rasche L, Angtuaco E, McDonald J, Buros A, Stein C, Pawlyn C, et al.
Blood
. 2017 Apr;
130(1):30-34.
PMID: 28432222
F-Fluorodeoxyglucose (FDG)-positron emission tomography (PET) and diffusion-weighted magnetic resonance imaging with background signal suppression (DWIBS) are 2 powerful functional imaging modalities in the evaluation of malignant plasma cell (PC) disease...